Intech Investment Management LLC Acquires 5,823 Shares of Neurocrine Biosciences, Inc. $NBIX

Intech Investment Management LLC increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 16.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 40,478 shares of the company’s stock after purchasing an additional 5,823 shares during the quarter. Intech Investment Management LLC’s holdings in Neurocrine Biosciences were worth $5,741,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. AlTi Global Inc. increased its stake in Neurocrine Biosciences by 1.0% during the 3rd quarter. AlTi Global Inc. now owns 6,828 shares of the company’s stock worth $959,000 after purchasing an additional 70 shares in the last quarter. Huntington National Bank grew its holdings in shares of Neurocrine Biosciences by 12.6% during the fourth quarter. Huntington National Bank now owns 678 shares of the company’s stock worth $96,000 after buying an additional 76 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Neurocrine Biosciences by 0.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 11,112 shares of the company’s stock worth $1,560,000 after buying an additional 77 shares in the last quarter. Perigon Wealth Management LLC grew its holdings in shares of Neurocrine Biosciences by 3.1% during the fourth quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock worth $367,000 after buying an additional 78 shares in the last quarter. Finally, Signaturefd LLC grew its holdings in shares of Neurocrine Biosciences by 4.5% during the fourth quarter. Signaturefd LLC now owns 1,925 shares of the company’s stock worth $273,000 after buying an additional 83 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on NBIX. Citigroup increased their price objective on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. HC Wainwright boosted their price objective on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Wall Street Zen raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 25th. Wedbush boosted their price objective on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Finally, BMO Capital Markets cut their price objective on shares of Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a research report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $186.05.

Insider Activity

In other Neurocrine Biosciences news, Director Leslie V. Norwalk sold 3,810 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $155.01, for a total transaction of $590,588.10. Following the transaction, the director owned 2,429 shares of the company’s stock, valued at $376,519.29. The trade was a 61.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Charles Gorman sold 245,088 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $154.33, for a total value of $37,824,431.04. Following the transaction, the director directly owned 511,293 shares in the company, valued at $78,907,848.69. This trade represents a 32.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 278,786 shares of company stock worth $43,099,615. Corporate insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX opened at $158.30 on Monday. The firm has a market capitalization of $15.92 billion, a price-to-earnings ratio of 24.39, a price-to-earnings-growth ratio of 1.19 and a beta of 0.39. Neurocrine Biosciences, Inc. has a twelve month low of $121.42 and a twelve month high of $162.39. The stock’s 50 day moving average price is $139.36 and its two-hundred day moving average price is $139.08.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.